Andere talen Celularity Inc.

Aandelen

CELU

US1511902041

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,07 ^USD	-9,17%		-4,36%	+24,09%

26/03	Celularity ontvangt goedkeuring voor de Healthcare Common Procedure Coding System (HCPCS) Q-code van de U.S. Centers for Medicare & Medicaid Services voor Biovance 3L	CI
20/03	Celularity vraagt FDA weesgeneesmiddelstatus voor PDA-002 in facioscapulohumerale spierdystrofie	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Celularity Inc. to Host Investor and Analyst Research and Development Day	23/04
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing	22/04
Celularity Inc. to Host Investor and Analyst Research & Development Day	22/04
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing	19/04
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024	18/04
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024, Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products	16/04
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products	15/04
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells	08/04
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L	26/03
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	26/03
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy	20/03
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy	20/03
Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit	14/03
Celularity Inc. announced that it expects to receive $10 million in funding from Yorkville Advisors Global LP	13/03
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress	12/03
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells	07/03
Celularity to Execute Reverse Stock Split Next Week	23/02
Celularity Announces 1-for-10 Reverse Stock Split	23/02
Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease	14/02
Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline	01/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Celularity Inc.

Aandelen

CELU

US1511902041

Andere talen

Filters